TrialJournal of clinical pharmacology2024
Effects of Food, Gastric Acid Reduction, and Strong CYP3A Induction on the Pharmacokinetics of Tasurgratinib, a Novel Selective Fibroblast Growth Factor Receptor Inhibitor.
Maiko Nomoto et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.